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Converging evidence suggests that high levels of education and intellectual activity increase the cognitive reserve and reduce
the risk of dementia. However, little is known about the impact that different neuroprotective strategies may have on the
incidence of Alzheimer’s disease. Using a simple mathematical regression model, it is shown here that age-specific counts of
basic cognitive units (surrogate of neurons or synapses) in the normal population can be estimated from Alzheimer’s incidence
rates. Hence, the model can be used to test the effect of neuroprotection on Alzheimer’s incidence. It was found that the
number of basic cognitive units decreases with age, but levels off in older people. There were no gender differences after
correcting for survival. The model shows that even modest neuroprotective effects on basic cognitive units can lead to
dramatic reductions in the number of Alzheimer’s cases. Most remarkably, a 5% increase in the cognitive reserve would
prevent one third of Alzheimer’s cases. These results suggest that public health policies aimed at increasing the cognitive
reserve in the general population (e.g., implementing higher levels of education) are likely the most effective strategy for
preventing Alzheimer’s disease.
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INTRODUCTION
There is concern that the progressive loss of neurons and synapses
with age may lead to dramatic increases in incidence rates of late-
onset Alzheimer’s disease in future generations with greater
longevity [1]. However, while there is substantial evidence that
normal aging is associated with some cognitive impairment, the
relationship between Alzheimer’s disease, normal aging, and brain
function is still far from clear [2–5]. It has been shown that most
people accumulate Alzheimer-related lesions with age [6], but
there is still controversy as to whether neuron death (or synapse
density loss) is an inevitable result of normal aging [7]. Conversely,
advanced Alzheimer’s pathology is sometimes associated with
normal cognition [8]. These observations highlight a considerable
disjunction between pathology and function in the aging brain,
and support the notion that the cognitive reserve plays a crucial
role in modifying the relationship between pathology and cognitive
function [9,10]. Indeed, there is converging evidence that
education and cognitive activity have protective effects on
cognition, reducing the risk of dementia [11–14].
The main objective of this study was to evaluate the effect of
neuroprotection on Alzheimer’s disease incidence. From a func-
tional viewpoint, normal cognition depends on the contribution of
a number of basic cognitive units (BCU), which may represent
neurons, synapses or cerebral circuits (biological units). The
cognitive reserve refers to the number of BCU an individual has to
lose before developing dementia symptoms [10]. Age-specific
incidence rates of Alzheimer’s disease reflect the instantaneous
probability of BCU counts dropping below a certain threshold,
which separates normal cognition from dementia. Consequently,
reported incidence rates of Alzheimer’s disease can be used to
model and ‘visualize’ the effect of aging on BCU counts in the
normal (living) population. Most importantly, this simple mathe-
matical model offers a unique method to estimate the effect of
neuroprotection on Alzheimer’s disease incidence. Several ob-
servations support the model: 1) Virtually the entire population
has Alzheimer-related pathology (amyloid plaques and neurofi-
brillary tangles) by age 90 years [6]; 2) The hippocampus is
targeted by both normal aging and Alzheimer’s disease [7]; and 3)
Synapse density loss seems to be the major correlate of cognitive
impairment in both normal aging and Alzheimer’s disease [11].
METHODS
Data: Epidemiological studies
A Medline/PubMed search of the English literature between 1966
and the end of 2005 identified 26 studies on the incidence of
Alzheimer’s disease that met the inclusion criteria. Studies were
selected according to the following inclusion criteria: 1) Case
finding was based on a field survey with population-based samples;
2) Males and females were included in the study; 3) Age-specific
incidence rates of Alzheimer’s disease were reported for dementia
from mild to severe; 4) Standard errors of incidence rates were
reported or could be calculated from the reported data. There
were 11 studies from Europe [15–25], 8 studies from North
America [26–33], 4 studies from Asia [34–37], 1 study from Africa
[38], 1 study from Australia [39], and 1 study from South America
[40]. Sixteen studies included specific data for women and men.
Some of these 26 studies were included in previous meta-analyses
and review articles [41–45].
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The model assumes that 1) BCU counts are approximately
normally distributed at any given age, and 2) Alzheimer’s disease
occurs when BCU counts drop below a certain threshold value
(symptom threshold). Therefore, as incidence rates of Alzheimer’s
disease represent the probability (p) of failure in cognition at any
given age, age-specific z-scores can be directly obtained from these
p values. Re-arranging the formula of the z-score, the following
equation is obtained: E(y|x)=c2z-score6SD(y|x), where c repre-
sents the symptom threshold, E(y|x) is the expected BCU count (y)
at any given age (x), and SD(y|x) is the corresponding standard
deviation.
It should be noted that post-mortem studies support the model
assumption that BCU counts are approximately normally
distributed at any given age, and suggest that Alzheimer’s
symptoms appear when the BCU count drops to about 50% the
normal value at an early age (say, age 20 years) [11,46–51].
Hence, the BCU count can be expressed as a proportion, using
c=0.5 as the most likely threshold value. Regression analyses of
previous post-mortem studies also suggest that SD(y|x)=0.1 is the
most likely value for the standard deviation. Consequently, the
final equation is E(y|x)=BCU|age=0.520.16z-score. Sensitivity
analyses were carried out to evaluate the effect of changing these
parameter values.
Statistical analysis
Average annual age-specific incidence rates of Alzheimer’s disease
(per 1,000 person-years) were estimated from the reported
incidence rates using two different non-parametric regression
methods, loess and sm [52–54]. As rates are always restricted (i.e.,
they can only take positive values), a log transformation was used
in the regression analysis, where log is the natural logarithm. The
estimated age-specific average values were then converted back
to the original scale, which gives the average p at any given age,
from which the corresponding z-scores were directly obtained.
These z-scores were then incorporated into the final equation
BCU|age=0.520.16z-score, obtaining thus the BCU curve. The
smoothing parameter was selected according to the cross-
validation criterion in each regression analysis [52–54]. The
inverse variances of log incidence rates of Alzheimer’s disease were
used as weights, which are proportional to the number of incident
Alzheimer’s cases [55]. The same non-parametric weighted
regression methods were also applied to the different E(y|x) values
obtained directly from the reported incidence rates for each study.
Gender comparisons were performed using weighted non-
parametric methods (sm ancova and generalized additive models
using loess) [53].
RESULTS
Estimates of basic cognitive units (BCU)
Non-parametric fits of log incidence rates of Alzheimer’s disease
on age (Fig. 1), and the corresponding BCU curves (Fig. 2), were
found to depart significantly from linearity (sm regression,
P,0.0001). Thus, BCU counts decrease with age in the normal
population up to around age 85 years and then tend to level off.
Sensitivity analysis demonstrated consistency in the overall pattern
of the BCU curve i) after changing the values for c and SD, ii)
using age-dependent SD values (either age-related increase or age-
related decrease of SD), and iii) using non-constant sm smoothing
parameters.
The BCU curves obtained for women and men also showed
a similar overall pattern, with a leveling off at advanced age (Fig. 3).
However, while the female and male BCU curves run in close
proximity up to age 75 years, women deteriorate further at older
ages. This difference was statistically significant (for log incidence
rates of Alzheimer’s disease: sm ancova, P,0.001; generalized
Figure 1. Non-parametric regression of the natural logarithm (log) of
Alzheimer’s incidence rates on age. Rates were estimated per 1,000
person-years. The diameter of the circles for each data point is
proportional to the square root of the number of Alzheimer’s cases. For
visibility, very small circles have been replaced by asterisks. The solid
and dashed curves were obtained by weighted non-parametric
regression methods using sm and loess, respectively (see Methods);
the smoothing parameter corresponded to span=1 in both cases [52–
54]. The two curves closely agree and depart significantly from a linear
model (sm regression, P,0.0001). There was no evidence for non-
constant variance (score test, P=0.88).
doi:10.1371/journal.pone.0000052.g001
Figure 2. Non-parametric regression of the number of basic cognitive
units (BCU) on age. The BCU count is expressed as a proportion with
respect to the average normal BCU count at an early age (say, age
20 years). Again, circle sizes are proportional to the square root of the
number of Alzheimer’s cases, asterisks represent very small circles, the
solid curve was obtained using sm, and the dashed curve was obtained
using loess (span=1). Data points were directly derived from the
z-scores associated with the corresponding Alzheimer’s incidence rates,
using the equation: BCU|age=0.520.16 z-score, where the threshold
(c) is 0.5, and the standard deviation (SD) is 0.1 (see Methods). The
plotted curves were derived from the average annual incidence rates of
Alzheimer’s disease (see Fig. 1), but virtually identical curves were
obtained by direct weighted non-parametric regression of BCU points
on age. Again, both BCU curves closely agree and depart significantly
from linearity (sm regression, P,0.0001). Thus, BCU counts decrease
with age up to approximately age 85 years, and then level off.
doi:10.1371/journal.pone.0000052.g002
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curves become virtually identical at older ages (Fig. 4) after crude
adjustment for gender differences in survival using general
population data (generalized additive model for log incidence
rates of Alzheimer’s disease including age-specific female/male
survival ratios as a covariate, P=0.16) [56,57].
Effect of neuroprotection
Two different types of neuroprotection were tested: 1) Cell-
rescuing therapies (Protect-1), which lead to increased number of
BCU at any given age; and 2) Neuroprotective strategies aimed at
increasing the cognitive reserve (Protect-2). The model shows that
for 5% neuroprotection in age-specific BCU counts (Protect-1), the
total number of Alzheimer’s cases is expected to decrease by 45%
between ages 65 and 94 years (Table 1); for 20% neuroprotection,
96% of Alzheimer’s cases would be prevented. On the other hand,
a 5% increase in the cognitive reserve (i.e., lowering of the
threshold value from 0.5 to 0.475; Protect-2) would save 34% of
Alzheimer’s cases in the age range 65–94 years (Table 1).
DISCUSSION
This study shows that the incidence rate of Alzheimer’s disease
increases with age but slows down at older ages. Although not all
[42], most previous meta-analyses found a similar deceleration in
incidence rates of Alzheimer’s disease [41,43,44]. The model
consistently shows that the number of BCU decreases with age but
tends to reach a plateau at advanced age. This observation likely
reflects the combination of two different phenomena: 1) The
earlier development of dementia in subjects at higher risk (e.g.,
carriers of the apolipoprotein e4 allele), which then gives rise to
a healthier normal population; and 2) A within-subject constant (or
decreasing) risk of neuron death with age, which has experimen-
tally been shown to govern cell kinetics in Alzheimer’s disease and
other neurodegenerative disorders [58]. It should be emphasized
that while different threshold and variance values give different
BCU curves, the overall pattern of the curve (i.e., a leveling off at
older ages) is mostly independent of these parameter values and
consistently suggests a decreasing risk of neuron death at advanced
age. In fact, Fig. 3 shows that the average BCU count may indeed
increase in older men. This result is in keeping with recent post-
mortem results [59], and suggests that men surviving to advanced
age might represent a ‘super-normal’ subpopulation [60].
The model also shows gender differences in BCU curves. There
is experimental evidence suggesting that estrogens likely have
a protective effect on cognitive function [7]. Therefore, it could be
argued that estrogen deprivation at advanced age might explain
why women have in general higher incidence rates of Alzheimer’s
disease compared to men [41–45]. However, the overall pattern of
the BCU curves (i.e., no gender difference up to age 75 years) is
difficult to reconcile with this notion. Likewise, constant gender
differences in the cognitive reserve (e.g., differences in the level of
education) should be associated with differences in BCU curves at
any given age, not simply in the older range. The most likely
explanation is a survival effect. Indeed, the female and male BCU
curves become virtually identical at older ages after correcting for
gender differences in survival (Fig. 4). This observation suggests
Figure 3. Non-parametric regression curves of basic cognitive units
(BCU) on age, for women and men. The overall pattern of these two
BCU loess curves was similar to that found for the total population (see
Fig. 2), with a leveling off at older ages. However, there were statistically
highly significant differences between women and men (generalized
additive model for log incidence rates of Alzheimer’s disease,
P=0.0015). While the two curves are very similar up to age 75 years,
women deteriorate more than men at older ages.
doi:10.1371/journal.pone.0000052.g003
Figure 4. Adjusted non-parametric regression curves of basic
cognitive units (BCU) on age, for women and men. There were no
statistically significant differences in BCU curves between women and
men after correcting for gender differences in survival (generalized
additive model for log incidence rates of Alzheimer’s disease, P=0.16).
doi:10.1371/journal.pone.0000052.g004
Table 1. Effect of neuroprotection on Alzheimer’s disease (AD)
......................................................................
Baseline Protect-1 Protect-2
Age (yrs) AD cases AD cases % AD cases %
65–69 1,640 482 71 753 54
70–74 3,353 1,140 66 1,653 51
75–79 6,501 2,595 60 3,488 46
80–84 11,600 5,569 52 6,936 40
85–89 16,337 9,548 42 11,119 32
90–94 16,222 11,450 29 12,689 22
Total 55,652 30,785 45 36,638 34
Baseline values are the expected number of cases of Alzheimer’s disease (AD) at
any given age (from an original at risk population of 100,000). These values
were obtained from the loess curve of basic cognitive units (see Fig. 2).
Neuroprotection obtained by 1) a 5% increase in the number of basic cognitive
units at any given age (Protect-1), and 2) a 5% increase in the cognitive reserve
(Protect-2).
doi:10.1371/journal.pone.0000052.t001
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in public heath care policies and services may tend to favor the
survival of relatively frail subjects, particularly at advanced age.
Hence, incidence rates of late-onset Alzheimer’s disease are likely
to increase as the number of subjects surviving to older ages
increases in future generations with longer life expectancy. For
example, if life expectancy of men increased to match the current
life expectancy of women, so too would the male incidence rate of
Alzheimer’s disease.
Most importantly, the model allows us to predict the impact of
preventive neuroprotective strategies on incidence rates of
Alzheimer’s disease [61]. Cell-rescuing neuroprotective therapies
are expected to slow down the rate of neuron loss. As the
probability that a neuron can be rescued from Alzheimer-related
pathology is not diminished by age [58], the model can be easily
accommodated to estimate the effect of cell-rescuing neuroprotec-
tion on incidence rates of Alzheimer’s disease. It was found that
even relatively modest neuroprotective effects on BCU counts can
lead to dramatic reductions in incidence rates of Alzheimer’s
disease. Nonetheless, these results could only be obtained if such
‘hypothetical’ neuroprotective treatment were universally applied
to the general population (with the additional problem of
treatment-related side effects).
A more realistic neuroprotective strategy, which has important
implications for public health decisions on putative preventive
methods for Alzheimer’s disease, refers to measures aimed at
increasing the cognitive reserve. There is a growing body of
evidence that higher levels of education and intellectual skills are
associated with less cognitive impairment [9–14]. Intellectual
activity likely improves the efficiency of brain networks and may
also increase the level of redundancy in BCU circuits (i.e., more
BCU need to be lost to reach the same level of cognitive
deterioration) [10]. The model shows that a 5% increase in the
cognitive reserve would prevent one third of Alzheimer’s cases in
the world. This result suggests that health policies aimed at
increasing the level of education in the general population, as well
as programs implementing cognitive training interventions, are
likely the most effective method of preventing Alzheimer’s disease.
In fact, preliminary results from randomized controlled trials have
already shown that cognitive stimulation slows down cognitive
decline [62,63].
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